Saxagliptin and Metformin
Brand Names: Saxagliptin and Metformin Generic
Methodology & AI Transparency ⓘ
Saxagliptin and Metformin Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Saxagliptin and metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus .
- 2 Real-world patient consensus: Tracked across 12 patient dosage logs with a 87% satisfaction benchmark (RxCUI 1043563).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $185.00 cash mean against $453.25 retail pharmacy pricing.
- 4 Top reported side effects / signs: Most commonly reported Saxagliptin and Metformin tolerability events: nausea (10%), diarrhea (7.3%), vomiting (3.6%).
Ask our AI Specialists anything about Saxagliptin and Metformin
Saxagliptin and Metformin Mechanism, CYP450 Pathways & DailyMed Monograph
Saxagliptin and metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . Saxagliptin and metformin hydrochloride extended-release tablets are a combination of saxagliptin, a dipeptidyl peptidase-4 (DPP4) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: ; Not recommended for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis.
12.1 Mechanism of Action Saxagliptin and Metformin Hydrochloride Extended-Release Tablets Saxagliptin and metformin hydrochloride extended-release tablets contain two antihyperglycemic medications: saxagliptin, a dipeptidyl-peptidase-4 (DPP4) inhibitor, and metformin HCl, a biguanide. Saxagliptin Increased concentrations of the incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are released into the bloodstream from the small intestine in response to meals.
Clinical clearance of Saxagliptin and Metformin (Biguanide) relies on mixed metabolic conjugation and unchanged urinary excretion across saxagliptin and metformin regimens with a Terminal t½ estimated at 4–17 hrs depending on renal/hepatic reserve (Saxagliptin and Metformin) half-life; patients absorbing at F ≈ 79%–91% systemic availability after standard oral Saxagliptin and Metformin administration bioavailability typically observe target onset around time to peak concentration spans 1 to 3 hrs under saxagliptin and metformin maintenance.
FDA clinical labeling for Saxagliptin and Metformin restricts administration in saxagliptin and metformin hydrochloride extended-release tablets are contraindicated in patients with:; severe renal impairment (egfr below 30 ml/min/1.73 m 2 ).; acute or chronic metabolic acidosis, including diabetic ketoacidosis. across 5 mg/1 / 500 mg/1 Tablet, Film Coated, Extended Release, 2.5 mg/1 / 1000 mg/1 Tablet, Film Coated, Extended Release, 5 mg/1 / 1000 mg/1 Tablet, Film Coated, Extended Release, with self-reported patient tracking dominated by nausea (10% of reports), diarrhea (7.3% of reports), headache (6.7% of reports).
Assess baseline hepatic panels and interacting prescriptions when starting Saxagliptin and Metformin (biguanide).
Unstandardized herbal extracts may interact pharmacodynamically with Saxagliptin and Metformin maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Saxagliptin and metformin hydrochloride extended-release tablets are contraindicated in patients with:
- Severe renal impairment (eGFR below 30 mL/min/1.73 m 2 ).
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis.
Logged Side-Effect Incidence (12 Reports)
Saxagliptin and Metformin Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Saxagliptin and Metformin)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of dapagliflozin plus saxagliptin vs single-drug treatment as: What a 7,346-Participant Study Found Patients taking the DSM therapy had better effects in reducing the level of HbA1c, FPG, body weight, SBP and DBP than the DM and SM therapy. Medicine • 2020-07-24 • Meta-Analysis | N = 7,346 | 94/100 | PMID 32791755 ↗ |
| New Insights on Benefits and safety of dapagliflozin or dapagliflozin plus saxagliptin versus: What a 939-Participant Study Found Dapagliflozin, saxagliptin and metformin improved glycaemic control compared with glimepiride plus metformin; add-on of dapagliflozin alone showed efficacy similar to that of glimepiride. Diabetes, obesity & metabolism • 2018-11-15 • Randomized Controlled Trial | N = 939 | 93/100 | PMID 29947099 ↗ |
| New Insights on Benefits and safety of saxagliptin added to metformin in Asian people with type 2: What a 283-Participant Study Found Saxagliptin added to metformin significantly improved blood sugar control and was well tolerated in Asian patients with T2DM who had inadequate blood sugar control with metformin and diet and lifestyle modification. Diabetes research and clinical practice • 2011-11-15 • Randomized Controlled Trial | N = 283 | 93/100 | PMID 21871686 ↗ |
| Can This Approach Help? Inside the Latest Research on Safety, Growth, and Development After Dapagliflozin or Saxagliptin in Children Prior treatment with dapagliflozin or saxagliptin for 52 weeks did not raise any safety concerns relating to height, weight, BMI, Tanner staging, growth and maturation markers, bone biomarkers, or AEs for up to 52 weeks... The Journal of clinical endocrinology and metabolism • 2025-05-19 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39446459 ↗ |
| Can This Approach Help? Inside the Latest Research on Dual add-on therapy in type 2 diabetes poorly controlled with metformin In this first report of adding a well-tolerated combination of saxagliptin plus dapagliflozin to background metformin therapy in patients poorly controlled with metformin, greater improvements in blood sugar control were... Diabetes care • 2015-03-15 • Phase III Randomized Trial | N = 176 | 88/100 | PMID 25352655 ↗ |
Saxagliptin and Metformin Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $9.3906/unit (~$281.72/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $453.25 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 12 Anonymous DotMD Community Micro-Logs | $185.00 / mo | View logs ↓ |
Saxagliptin and Metformin Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Saxagliptin and Metformin RxNorm Concept ID | 1043563 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $9.3906 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $453.25 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $185.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 87.00% Worth It (12 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Saxagliptin and Metformin Patient Community, Cohort Filters & Dosage Logs
Cross-verified Saxagliptin and Metformin (biguanide) monograph synthesizing RxNorm 1043563, openFDA FAERS signals, and $185.00–$453.25 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Saxagliptin and Metformin community threads and patient logs by age, biological sex, dosage, and treatment duration.